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Abstract
Background Pulmonary interstitial glycogenosis (PIG)
arises from a developmental disorder of the pulmonary
mesenchyme and presents clinically with reversible neo-
natal respiratory distress and/or persistent pulmonary
hypertension of the newborn (PPHN).
Objective We report two cases of PIG in patients
with congenital heart disease (CHD) and evidence of
PPHN.
Results Both cases demonstrated the hallmark PIG his-
tologic finding of diffuse, uniform interstitial thickening
due to the presence of immature interstitial cells containing
abundant cytoplasmic glycogen.
Conclusions We report the second and third patients with
PIG associated with CHD. Because histologic examination
is required to establish the diagnosis, we speculate that
PIG, although rare, may be underrecognized in neonates
presenting with PPHN in the setting of CHD.
Keywords Congenital heart defects  Glycogen storage
diseases  Interstitial lung diseases  Neonatal respiratory
distress syndrome  Persistent pulmonary hypertension of
the newborn
Introduction
Pediatric interstitial lung disease has an estimated preva-
lence of 1.3 to 3.6/1,000,000 [5, 6]. Although interstitial
lung disease is a relatively uncommon cause of respiratory
distress in the neonatal period, multiple types have been
described. The majority of these types are genetic,
inflammatory, or infectious in etiology. The diagnosis of
interstitial lung disease is made based on the history,
physical examination, imaging results, and, when deemed
necessary and if feasible, results of more invasive diag-
nostic studies, including pulmonary function studies,
bronchoalveolar lavage, and lung biopsy. Treatment of
pediatric interstitial lung disease generally involves sup-
portive care as well as anti-inflammatory medications [3].
Pulmonary interstitial glycogenosis (PIG), unlike most
types of pediatric interstitial lung disease, arises from a
developmental disorder. The etiology of the defect involves
abnormal differentiation of the pulmonary mesenchyme.
This abnormal differentiation results in the abundance of
glycogen in pulmonary interstitial cells. The disorder most
often presents in neonates with respiratory distress, with or
without evidence of pulmonary hypertension, and diffuse
interstitial infiltrates on chest radiograph. As with all
interstitial lung diseases, the definitive diagnosis is made
by histologic examination. For PIG, the hallmark histologic
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finding is diffuse, uniform interstitial thickening due to the
presence of immature interstitial cells containing abundant
cytoplasmic glycogen [7]. Treatment is supportive. Corti-
costeroid therapy is often effective. The efficacy of steroids
is thought to relate to the acceleration of cellular matura-
tion and not modulation of inflammation. The prognosis in
PIG is more favorable than the majority of other pediatric
interstitial lung diseases, but the reason for this remains
unknown [1]. However, it may be fatal or associated with
chronic lung disease.
We report two cases of PIG in patients with congenital
heart disease (CHD) and clinical evidence of PPHN. To our
knowledge, there is only one previous report of a patient
with CHD and PIG in the literature. Unexplained PPHN
can be associated with, and complicate the course of,
neonates with CHD. Because histologic examination is
required to establish the diagnosis, we speculate that PIG, a
rare but potentially treatable form of PPHN, may be under-
recognized in neonates presenting with PPHN in the setting
of CHD.
Case Report: Patient No. 1
This term, female infant was hypotonic and cyanotic shortly
after an uncomplicated vaginal birth with saturations in the
70s on 100% oxygen masked with continuous positive air-
way pressure. The results of the initial arterial blood gas
analysis were pH 7.25, partial pressure of carbon dioxide 58,
partial pressure of oxygen 32, and base deficit -5. Umbilical
catheters were placed; blood cultures were obtained; empiric
antibiotic treatment was initiated; and transport was arran-
ged to the UCSF neonatal intensive care unit (NICU). Initial
as well as all subsequent blood cultures remained negative
throughout the hospital course. Chest X-ray showed dif-
fusely hazy lung fields with a normal cardiac silhouette. The
patient was intubated due to persistent cyanosis and low
oxygen saturations. Cyanotic CHD was suspected, and
prostaglandin and dopamine continuous infusions were
started to maintain ductal patency and adequate systemic
blood pressure, respectively.
On arrival to the UCSF NICU, echocardiogram was
obtained that showed d-transposition of the great arteries
with normal coronary artery pattern, intact ventricular sep-
tum, patent foramen ovale with left-to-right shunting, large
patent ductus arteriosus (PDA) with all left-to-right shunt-
ing, and normal ventricular function. The patient’s initial
ICU course was remarkable for significant hemodynamic
instability and hypoxemia despite positive-pressure
mechanical ventilation, volume administration, and inotro-
pic support with dopamine and epinephrine infusions. There
was no response to inhaled nitric oxide. On hospital day 3,
the patient was given a stress-dose of hydrocortisone in
response to profound hypotension refractory to inotropes,
which was concerning for cortisol deficiency. Marked
clinical improvement occurred within 24 h of initiating
steroid therapy. The epinephrine infusion was discontinued,
and the dopamine infusion and inhaled nitric oxide were
weaned. Two days later, the neonate required increasing
inotropic support, and a second stress-dose of hydrocorti-
sone was administered. Shortly after the initiation of the
second steroid course, once again, her respiratory status
improved dramatically. Inhaled nitric oxide was weaned,
and the patient was successfully extubated. Subsequent
serum adrenocorticotropic hormone and cortisol levels,
drawn before the administration of steroids, returned to 10
and 15 lg/dL, respectively; both were within the range of
normal, suggesting adequate adrenal function.
On hospital day 13, the patient underwent arterial switch
surgery, at which time an intraoperative lung biopsy
specimen was performed. The surgical biopsy specimen
showed patchy alveolar septal thickening by ovoid cells
that were highlighted by periodic acid Schiff (PAS) stain,
consistent with PIG [9, 11]. There was mild to moderate
medial hypertrophy of the pulmonary arteries (Fig. 1).
The patient’s postoperative recovery was uncompli-
cated. Her pre-discharge echocardiogram showed intact
arterial switch procedure results with mild tricuspid valve,
pulmonary valve, and neo-aortic valve regurgitation, nor-
mal left-ventricular systolic function, and normal right-
ventricular pressure and function. She was discharged
home on hospital day 24.
Case Report: Patient No. 2
This 37-day-old term infant boy presented shortly after
birth with a murmur on cardiac auscultation and was ini-
tially diagnosed with tetralogy of Fallot. Shortly after birth,
his saturations were in the mid 90s. However, during the
subsequent 3 weeks, his oxygen saturations decreased to
the low 70s. The parents did not report hypercyanotic
spells, but he was tachypneic with feeds. His preadmission
echocardiogram showed a mean transpulmonary gradient
of 50 mmHg with a peak of 80 mmHg. He was admitted
for observation and preoperative evaluation. Before sur-
gery, he maintained saturations in the high 80s to low 90s
with supplemental oxygen delivered by nasal cannula at a
flow of  L/min.
The patient underwent surgical repair on day of life 39,
at which time preoperative transesophageal echocardio-
gram demonstrated heterotaxy syndrome (left atrial isom-
erism), double-outlet right ventricle, ventricular septal
defect (VSD) with pulmonary stenosis with anomalous
drainage of the right pulmonary veins to the right atrium,
interrupted infrahepatic inferior vena cava with azygous
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continuation to the right superior vena cava, left superior
vena cava that drained to the coronary sinus, and right-
sided aortic arch with an aberrant left subclavian artery. He
underwent surgical repair, which entailed a pulmonary
arterioplasty to relieve the supravalvar stenosis, resection
of the obstructing right-ventricular muscle bundles, closure
of the VSD, division of the vascular ring, and baffling of
the right partial anomalous pulmonary venous drainage to
the left-sided atrium. Notably, before sternal closure, the
distal pulmonary artery pressures and the right ventricular
pressure were near systemic. Evaluation did not demon-
strate any residual defects to account for these findings, and
the pulmonary artery pressures were unresponsive to a trial
of inhaled nitric oxide. Therefore, a lung biopsy specimen
was obtained to investigate the etiology of the pulmonary
arterial hypertension. The patient’s initial postoperative
course was unremarkable, and his trachea was extubated on
postoperative day 1. Due to persistent systemic right-ven-
tricular pressures demonstrated on postoperative echocar-
diograms, therapy with sildenafil was initiated, and
supplemental oxygen was administered to promote pul-
monary vascular relaxation. The results of the intraopera-
tive lung biopsy became available approximately 1 week
after the surgery and showed PIG. Specifically, the sections
contained diffuse alveolar septal thickening by numerous
PAS-positive ovoid cells and minimal fibrosis. The pul-
monary arteries were only minimally thickened. A paucity
of T cells and B cells was noted.
Steroids were considered, but in contrast to patient no. 1,
they were not given because the infant’s clinical course
was one of gradual improvement with decreasing tachyp-
nea. Subsequent echocardiogram demonstrated intact sur-
gical repair results with no residual septal defects, mild to
moderate tricuspid valve regurgitation, mild pulmonary
valve regurgitation, and normal left-ventricular systolic
function. Right-ventricular pressure was estimated at
approximately 40 % systemic values. The infant was dis-
charged on hospital day 39, with respiratory rates in the 40s
to 50s, and oxygen saturations in the high 90s on supple-
mental oxygen by nasal cannula at  L/min flow.
Discussion
We report, to the best of our knowledge, the second and
third cases of PIG associated with CHD. Both patients
presented with either clinical evidence (patient no. 1) or
documentation (patient no. 2) of perioperative pulmonary
hypertension that was clinically significant and unrespon-
sive to inhaled nitric oxide. Interestingly, in patient no. 1,
systemic steroid therapy was initiated before the diagnosis
of PIG was made. Steroids were given for suspected, and
subsequently disproved, adrenal insufficiency and were
associated with clinical improvement. In patient no. 2,
clinical improvement was gradual without steroid admin-
istration. Both cases demonstrated the hallmark PIG his-
tologic finding of diffuse, uniform interstitial thickening
due to the presence of immature interstitial cells containing
abundant cytoplasmic glycogen. Moreover, both cases
demonstrated evidence of increased pulmonary pressures,
which led to the administration of inhaled nitric oxide and,
in the second case, long-term treatment with sildenafil.
Persistent pulmonary hypertension of the newborn is not
a single disease but rather a pathophysiologic condition. It
is a clinical syndrome that manifests when the normal
transition from the fetal to the postnatal pulmonary circu-
lation fails to occur. In other words, the acronym ‘‘PPHN’’
encompasses the spectrum of diseases in which the normal
sharp decrease in pulmonary vascular resistance and
increase in pulmonary blood flow, with concomitant
Fig. 1 a A low-power view of the surgical lung biopsy specimen
shows diffuse alveolar septal widening by interstitial cells. The
pulmonary arteries surrounding the alveolar septum (green arrow)
show moderate medial thickening (red arrow) (hematoxylin-and-
eosin stain [910]). b A high-power view shows granular cytoplasmic
glycogen accumulation with the interstitial cells (PAS stain [940])
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decrease in extrapulmonary shunting across the foramen
ovale and DA, is significantly delayed [8]. The patho-
physiologic mechanisms that prevent the normal pulmon-
ary vascular remodeling and vasodilation at birth remain
unclear, but they are most likely multifactorial in etiology.
Several conditions, including sepsis, meconium aspiration
syndrome, and lung hypoplasia, have been associated with
PPHN [2, 10]. Not surprisingly, the response to therapy
varies across etiologies and depends in part on the condi-
tion of the lung parenchyma and pulmonary vasculature.
Moreover, some conditions that cause PPHN—such as
alveolar capillary dysplasia (ACD) and pulmonary lym-
phangiectasias, particularly when it persists beyond the
neonatal period as in seen patient no. 2—are almost
entirely unresponsive to therapy. Thus, the ability to dis-
tinguish between the various conditions that result in PPHN
to plan appropriate diagnostic studies, tailor therapies, and
predict outcome remains crucial. It is recognized that
PPHN may be an independent complicating factor in the
preoperative and postoperative course of some neonates
with CHD with severe hypoxemia and hemodynamic
instability [12]. To date, potential etiologies for the inde-
pendent association between PPHN and CHD have not
been recognized.
Deutsch et al. [4] reported the first and only other doc-
umented case of PIG in a neonate with CHD. Similar to our
cases, that neonate presented with severe pulmonary
hypertension in the newborn period that could not be
explained by the diagnosed CHD of hypoplastic aortic arch
and PDA. Preoperative lung biopsy specimen demonstrated
PIG, and systemic steroid therapy was initiated with
marked clinical improvement. Interestingly, follow-up
biopsy specimen at 2 months of age demonstrated resolu-
tion of the pathology.
We report two additional cases of PIG in neonates with
CHD and evidence of unexplained pulmonary hypertension
of the newborn. Because histologic examination is required
to establish the diagnosis, we speculate that PIG, although
rare, may be underrecognized in neonates presenting with
PPHN in the setting of CHD. Moreover, although corti-
costeroids are the ‘‘gold-standard’’ therapy in biopsy-con-
firmed PIG, the consequences of this treatment, i.e.,
potential neurodevelopmental aberrations, immunosup-
pression, poor wound healing, and potential decreased
pulmonary alveolarization in patients suffering from con-
comitant lung growth anomalies, must be considered
because PIG is often a self-limited disease process.
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